|
Switzerland Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Switzerland Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Switzerland.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Swiss pharmaceutical and healthcare industry.
Competitive intelligence, Swiss pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Swiss market.
The Switzerland Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Switzerland Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Swiss pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Switzerland to test other views – a key input for successful budgeting and strategic business planning in the Swiss pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Swiss Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Switzerland.
- Exploit The Latest Competitive Swiss Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Switzerland.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Switzerland Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Table: Switzerland Pharmaceuticals And Healthcare Industry SWOT |
| Switzerland Economic SWOT |
| Switzerland Political SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Western Europe Pharmaceutical Business Environment Rankings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Switzerland – Market Summary |
| Regulatory Regime |
| Recent Regulatory Developments |
| Recent Approvals |
| Intellectual Property Regime |
| Pricing Regime |
| Recent Pricing System Developments |
| Table: A Comparison Of Medicine Prices In Western Europe |
| Reimbursement Regime |
Chapter - Industry Developments |
| Epidemiology |
| Table: Disease Burden In Western Europe |
| Health Insurance |
| Healthcare Sector Financing |
| Pharmaceutical Sector |
| Pharmaceutical Wholesale and Retail Sector |
| Company Developments |
| Research And Development Sector |
| Biotechnology Sector |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Switzerland – Pharmaceutical Expenditure Indicators, 2004-2013 (CHFmn unless stated) |
| Key Growth Factors – Industry |
| Table: Switzerland – Health Expenditure Indicators, 2004-2013 (CHFmn unless otherwise stated) |
| Key Growth Factors – Macroeconomic |
| Table: Switzerland - Macroeconomic Forecasts |
| Prescription Market Forecasts |
| Table: Switzerland – Prescription Market Indicators, 2004-2013 (CHFmn unless otherwise stated) |
| OTC Market Forecast |
| Table: Switzerland – OTC Market Indicators, 2004-2013 (CHFmn unless otherwise stated) |
| Patented Market Forecasts |
| Table: Switzerland – Patented Pharmaceutical Market Indicators, 2004-2013 (CHFmn unless otherwise stated) |
| Generics Market Forecasts |
| Table: Switzerland – Generics Market Indicators, 2004-2013 (CHFmn unless otherwise stated) |
| Export/Import Forecasts |
| Table: Switzerland – Pharmaceuticals Export And Import Indicators (US$mn), 2004-2013 |
| Other Healthcare Forecasts |
| Other Healthcare Forecasts |
| Table: Switzerland – Other Healthcare Indicators, 2004-2013 |
| Medical Devices |
| Table: Switzerland Medical Device Market Indicators, 2006-2012 (US$bn unless otherwise stated) |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Monitor |
| Leading Multinational Manufacturers |
| GlaxoSmithKline (GSK) |
| Pfizer |
| Sanofi-Aventis |
| Merck & Co |
| Indigenous Manufacturers |
| Novartis |
| Roche |
| Merck-Serono |
Chapter - Country Snapshot: Switzerland Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Switzerland Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Swiss pharmaceutical market witnessed a minor slowdown in 2008, with data released from industry association Interpharma showing sales increasing by 5.3% versus 2007. Reduced growth levels have been attributed to widespread price cuts in March 2008, which shaved an estimated CHF93mn (US$77mn) off the drugs bill.
Into 2009, the global financial crisis is expected to further dent the market, with Switzerland’s large financial services industry meaning that a contraction in GDP is likely. For the drug market, we predict a compound annual growth rate of 2.3% from 2008-2013 in Swiss Francs, with drug expenditure reaching CHF6.6bn (US$5.6bn) in 2013.
Generics continued to capture market share, capturing 32% of sales by volume. Patented medicines were down 13% by volume. The average level of generic substitution in the eligible market was 70%, well above the European average. BMI believes the next five years will see a continued shift towards generic medicines in value terms. However, reinforcing the market potential for innovative medicines, demand for products launched from 2007-2008 grew 6.4%, whereas those launched in 2006 declined 1.1%.
The start of 2009 saw another round of price cuts, which will be a key constraint on growth. Interpharma sees the introduction of new biosimilars as another key factor for reducing market expansion, a view that BMI shares. The association also called for more prompt introduction of new medicines, suggesting Switzerland lags behind other countries in making new cancer drugs available through health insurers. A recent study into cancer treatments across Europe highlighted that Switzerland was behind many countries in terms of the number of new cancer treatments available to patients. However, in terms of average time delay between approval and market access, and overall spending on innovative products, the country performed well.
Switzerland remains an attractive prospect for the pharmaceutical industry as demonstrated by our Q209 Business Environment Rankings, which place the country second out of eight pharmaceutical markets surveyed in the Western Europe region. In addition to its high pharmaceutical spending, attractions include a strong regulatory climate, which is recognised by the US and EU, and a favourable corporate tax environment when compared with many of its European neighbours.
|
Switzerland Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |